创胜医药
TRANSCENTA

Transcenta Holding Limited
創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, JUNE 30, 2026; (2) CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES; AND (3) NON-COMPLIANCE WITH RULES 3.10(1), 3.21 AND 3.27A OF THE LISTING RULES

The board of directors (the "**Board**") of Transcenta Holding Limited (the "**Company**") is pleased to announce the poll results of the Annual General Meeting (the "**AGM**") held on Tuesday, June 30, 2026.

For details of the resolutions considered at the AGM, Shareholders may refer to the notice of the AGM and the Company's circular dated June 8, 2026 (the "**Circular**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The AGM was convened as an on-site meeting at B6-501, 218 Xinghu Street, Biobay, Suzhou, China on June 30, 2026 at 10 a.m. and all the proposed resolutions as set out in the notice of the AGM dated June 8, 2026 were taken by poll. The poll results are as follows:

Ordinary Resolutions*		Number of Votes (Approximate %)		Total number of votes cast
		For	Against	
1.	To receive and adopt the audited consolidated financial statements and the reports of the directors and auditor for the year ended 31 December 2025.	216,112,534 (99.98%)	49,000 (0.02%)	216,161,534
2(a).	To re-elect Dr. Xueming Qian as an executive director of the Company.	216,112,534 (99.98%)	49,000 (0.02%)	216,161,534
2(b).	To re-elect Ms. Helen Wei Chen as an independent non-executive director of the Company.	216,161,534 (100.00%)	0 (0.00%)	216,161,534
2(c).	To authorize the board of directors to fix the respective directors' remuneration.	216,161,534 (100.00%)	0 (0.00%)	216,161,534

Ordinary Resolutions*		Number of Votes (Approximate %)		Total number of votes cast
		For	Against	
3.	To appoint Dr. Hansen Xu as a non-executive director of the Company.	216,161,534 (100.00%)	0 (0.00%)	216,161,534
4.	To appoint Dr. Jun Bao as an independent non-executive director of the Company.	90,641,221 (41.93%)	125,520,313 (58.07%)	216,161,534
5.	To re-appoint Ernst & Young as auditor of the Company and to authorize the board of directors to fix its remuneration.	216,161,534 (100.00%)	0 (0.00%)	216,161,534
6.	To give a general mandate to the directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any shares that are held as treasury shares) as at the date of passing of this resolution.	216,161,534 (100.00%)	0 (0.00%)	216,161,534
7.	To give a general mandate to the directors to issue, allot and deal with additional shares (including any sale or transfer of shares out of treasury that are held as treasury shares) of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any shares that are held as treasury shares) as at the date of passing of this resolution.	215,678,034 (99.78%)	483,500 (0.22%)	216,161,534
8.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares (including any sale or transfer of shares out of treasury that are held as treasury shares) in the capital of the Company by the aggregate number of the shares bought back by the Company.	215,678,034 (99.78%)	483,500 (0.22%)	216,161,534

* The full text of the resolutions was set out in the notice of AGM.

Notes:

(a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 3 and 5 to 8 above, they were duly passed as ordinary resolutions. As less than 50% of the votes were cast in favour of the resolution numbered 4, it was not passed as an ordinary resolution.

(b) As at the date of the AGM, the total number of shares of the Company in issue was 455,374,999 shares, of which 2,516,500 shares were treasury shares held by the Company and the said treasury shares are registered in the Company's name and were excluded from the total number of issued shares entitled to attend and vote on the proposed resolutions at the AGM.

(c) The Company had not exercised the voting rights of the said 2,516,500 treasury shares at the AGM. There were no shares entitling the holder to attend but abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

(d) As at the date of the AGM, (i) 16,509,612 unvested shares held by trustee of Success Connect Trust under Share Incentive Scheme of the Company; and (ii) 1,495,834 and 95,630 unvested shares held by trustees of Success Link International L.P. and Success Reach International Limited under Pre-IPO Equity Incentive Plan of the Company were required to and did abstain from voting on the proposed resolutions at the AGM in accordance with Rule 17.05A of the Listing Rules. Save as disclosed above, no Shareholders were required under the Listing Rules to abstain from voting on the resolutions at the AGM.

(e) None of the Shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

(f) Accordingly, in relation to all resolutions proposed at the AGM, the total number of shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 434,757,423 Shares.

(g) The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

(h) The AGM was convened by the Board and was presided over by Dr. Xueming Qian. Except for Ms. Helen Wei Chen who did not attend the AGM due to her other business engagements, all other Directors attended the AGM in person or by electronic means.

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

References are made to the announcement of the Company dated June 4, 2026 and the Circular. The Board is pleased to announce that Dr. Hansen Xu ("**Dr. Xu**") was elected as a non-executive director of the Company at the AGM, with effect from June 30, 2026.

Please refer to Appendix II to the Circular for the biographical details of Dr. Xu. As at the date of this announcement, there has been no change in such information.

The Board further announces that Dr. Kumar Srinivasan ("**Dr. Srinivasan**") and Mr. Zhihua Zhang ("**Mr. Zhang**") have resigned as independent non-executive directors of the Company, with effect from June 30, 2026. Upon their respective resignations as independent non-executive directors, (i) Dr. Srinivasan ceased to be the chairperson of the Remuneration Committee and a member of the Nomination Committee; and (ii) Mr. Zhang ceased to be the chairperson of the Nomination Committee, a member of the Audit Committee and a member of the Remuneration Committee. Each of Dr. Srinivasan and Mr. Zhang has confirmed that (i) he has no disagreement with the Board; and (ii) there are no matters relating to his resignation that need to be brought to the attention of the Stock Exchange or the Shareholders.

Following the appointment of Dr. Xu as director of the Company, (i) Dr. Xu has been appointed as a member of the Remuneration Committee; (ii) Ms. Helen Wei Chen has been appointed as the chairperson of the Remuneration Committee; and (iii) Dr. Xueming Qian has been appointed as the chairperson of the Nomination Committee, all with effect from June 30, 2026.

The Board would like to express its sincere gratitude to Dr. Srinivasan and Mr. Zhang for their valuable contributions to the Company during their tenure of office and extend its warm welcome to Dr. Xu on his appointment to the Board.

NON-COMPLIANCE WITH RULES 3.10(1), 3.21 AND 3.27A OF THE LISTING RULES

Following the resignation of Dr. Srinivasan and Mr. Zhang, (i) the number of independent non-executive Directors falls below the minimum of three independent non-executive Directors on the Board as required under Rule 3.10(1) of the Listing Rules; (ii) the number of members of the Audit Committee falls below the minimum of three members and the Audit Committee no longer comprises a majority of independent non-executive Directors as required under Rule 3.21 of the Listing Rules; and (iii) the Nomination Committee no longer comprises a majority of independent non-executive Directors as required under Rule 3.27A of the Listing Rules. In order to comply with Rules 3.10(1), 3.21 and 3.27A of the Listing Rules, the Company is endeavoring to identify a suitable candidate to fill the vacancy as soon as practicable and in any event within three months from the date of this announcement, and will make further announcement(s) as and when appropriate.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, June 30, 2026

As at the date of this announcement, the Board comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu and Dr. Hansen Xu as non-executive Directors and Mr. Jiasong Tang and Ms. Helen Wei Chen as independent non-executive Directors.